| Literature DB >> 32415045 |
Nahla A Azzam1, Abdulrahman Aljebreen1, Arwa Almuhareb1, Majid A Almadi2.
Abstract
Background/Aim: Inflammatory bowel disease (IBD) is a chronic disorder affecting patients' health-related quality of life (HRQoL) which adds to their disability. Little is known about the impact of the COVID-19 pandemic on HRQoL of IBD patients. We aimed to evaluate HRQoL in IBD patient's pre- and post-COVID-19 pandemic using the IBD-disk questionnaire and explore associations between socio demographic factors, disease types, severity and impaired HRQoL in patients with IBD. Patients andEntities:
Keywords: COVID-19; DISK; IBD-DI; disability; inflammatory bowel disease; quality of life
Mesh:
Year: 2020 PMID: 32415045 PMCID: PMC7739992 DOI: 10.4103/sjg.SJG_175_20
Source DB: PubMed Journal: Saudi J Gastroenterol ISSN: 1319-3767 Impact factor: 2.485
Characteristics of those who responded to the questionnaire
| Variable | Total cohort, | Crohn's disease, | Ulcerative colitis, | |
|---|---|---|---|---|
| Age (years) | 33.89 | 33.90 | 33.89 | 1.00 |
| Sex | ||||
| Male | 25 (42.37%) | 15 (37.50%) | 10 (52.63%) | 0.27 |
| Female | 34 (57.63%) | 25 (62.50%) | 9 (47.37%) | |
| Married | 39 (66.10%) | 27 (67.50%) | 12 (63.16%) | 0.74 |
| Having children | 31 (52.54%) | 22 (55.00%) | 9 (47.37%) | 0.58 |
| Monthly Income in Saudi Riyals (SR) | ||||
| less than SR 5000 | 10 (16.95%) | 7 (17.50%) | 3 (15.79%) | 0.98 |
| Around SR 5000 | 31 (52.54%) | 21 (52.50%) | 10 (52.63%) | |
| More than SR 5000 | 18 (30.51%) | 12 (30.00%) | 6 (31.58%) | |
| Disease status | ||||
| Active | 18 (30.51%) | 12 (30.00%) | 6 (31.58%) | 0.90 |
| Remission | 41 (69.49%) | 28 (70.00%) | 13 (68.42%) | |
| Severity of disease | ||||
| Mild | 5 (8.47%) | 1 (2.50%) | 4 (21.05%) | 0.05* |
| Moderate | 27 (45.76%) | 19 (47.50%) | 8 (42.11%) | |
| Severe | 27 (45.76%) | 20 (50.00%) | 7 (36.84%) | |
| Medications | ||||
| 5-ASA | 4 (6.77%) | 0 (0.00%) | 4 (21.05%) | <0.01* |
| Corticosteroids > 15 mg/day | 1 (1.69%) | 1 (2.50%) | 0 (0.00%) | |
| Immune modulators | 3 (5.08%) | 3 (7.50%) | 0 (0.00%) | |
| Biologics | 26 (44.07%) | 21 (52.50%) | 5 (26.32%) | |
| Immune modulators and biologics | 13 (22.03%) | 12 (30.00%) | 1 (5.26%) | |
| Immune modulators & 5-ASA | 5 (8.47%) | 1 (2.50%) | 4 (21.05%) | |
| 5-ASA, corticosteroids and biologics | 1 (1.69%) | 0 (0.00%) | 1 (5.26%) | |
| 5-ASA and biologics | 2 (3.39%) | 0 (0.00%) | 2 (10.53%) | |
| Corticosteroids and biologics | 4 (6.77%) | 2 (5.00%) | 2 (10.53%) | |
| Haemoglobin | 12.71 | 12.64 | 12.86 | 0.66 |
| C reactive protein | 13.97 | 11.13 | 19.96 | 0.19 |
*Statistically significant
Figure 1(a) Age comparison between patients with Crohn's disease and ulcerative colitis. (b) Comparison of the hemoglobin level between patients with Crohn's disease and ulcerative colitis. (c) Comparison of the CRP level of patients with Crohn's disease and ulcerative colitis
Figure 2(a) Comparison between the age of patients based on disease severity. (b) Comparison between the hemoglobin levels of patients based on disease severity. (c) Comparison between the CRP levels of patients based on disease severity
Difference between symptoms in the patients with IBD who had the disc assessment before and after the COVID-19 outbreak
| Variable | Before | After | Difference | 95% CI | |
|---|---|---|---|---|---|
| Abdominal pain | 3.67 | 2.36 | -1.03 | -2.39-0.32 | 0.13 |
| Regulating defecation | 4.27 | 3.53 | -0.73 | -1.93-0.46 | 0.22 |
| Interpersonal interaction | 1.70 | 2.20 | 0.50 | -0.54-1.54 | 0.33 |
| Education and work | 2.77 | 2.6 | -0.17 | -1.78-1.44 | 0.83 |
| Sleep | 2.40 | 3.07 | 0.67 | -0.83-2.17 | 0.37 |
| Energy | 3.97 | 3.57 | -0.4 | -1.75-0.95 | 0.55 |
| Emotions | 4.13 | 4.40 | 0.27 | -1.37-1.90 | 0.74 |
| Body image | 2.53 | 3.93 | 1.4 | -0.02-2.82 | 0.05* |
| Sexual functions | 1.63 | 2.24 | 0.61 | -0.61-1.82 | 0.31 |
| Joint pain | 2.84 | 3.87 | 1.03 | -0.12-2.18 | 0.08 |
*Statistically significant